In CRC, FMR1 can recognize m6A modification sites in the mRNA of key molecules involved in cancer occurrence and targeted therapy, such as epidermal growth factor receptor, and maintain their stability and expression in an m6A-dependent manner, thereby promoting tumorigenesis and metastasis of CRC [74]. The gene discussed is EGFR; the disease is colorectal carcinoma.